Synthetic Biology: Emerging Global Markets

  • November 2011
  • -
  • BCC Research

REPORT SCOPE

INTRODUCTION

STUDY GOAL AND OBJECTIVES

BCC’s goal for this study is to determine the specific applications and forecast global market demand for synthetic biology products over a 5-year period from 2011 to 2016. Our particular interest is to characterize and quantify the synthetic biology products market potential by product type and end use market segments. We also analyze the synthetic biology industry structure, competitors, and intellectual property landscape.

Synthetic biology markets reviewed in this report include enabling products, biologic components, integrated systems, and enabled products.

Our key objective is to present a comprehensive analysis of the emerging synthetic biology industry, with an emphasis on products and technologies that are commercially important in the 2011-to-2016 time period. Market segments with rapid growth rates are highlighted, as well as those segments with large market potential. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the synthetic biology industry.

The study will be particularly useful to companies supplying synthetic genes, oligonucleotides, DNA sequencing instruments, cell culture media, biofuels, specialty chemicals, pharmaceuticals, vaccines, microfluidics, and life sciences tools.

REASONS FOR DOING THE STUDY

Synthetic biology is a rapidly emerging biotechnology discipline with a wide range of applications. Despite its emerging status, synthetic biology provides a significant number of near-term commercial opportunities, and the list of new products and applications is continuously growing. These applications include specialty chemicals, enzymes, synthetic genes and other DNA parts, pharmaceuticals, biofuels, and chassis microorganisms.

It is important for companies in industries affected by the developments in synthetic biology to sort through the many potential applications to identify near-term commercial opportunities for product development focus. This report allows companies to prioritize product opportunities, establishing a solid framework for strategic planning.

Synthetic biology encompasses a wide range of industries including life science tools, biotechnology, pharmaceuticals, diagnostics, energy, and chemicals. Because of its wide scope, synthetic biology plays an important role in the future of the industrial economy.

Ongoing advances in enabling technologies such as DNA synthesis and sequencing, specialty media, and bioinformatics, as well as a need for renewable feedstocks, are driving the growth of synthetic biology. Rapid developments in these multidisciplinary fields promise to advance the synthetic biology industry and create unique market opportunities. This report analyzes these trends and their impact on the future markets for synthetic biology products.

Based on these market and technology dynamics, it is especially timely to examine the current and future synthetic biology markets.

INTENDED AUDIENCE

We have compiled a study of existing and future synthetic biology products and technologies that will be commercially important in the main end user segments of life science research, pharmaceuticals, diagnostics, energy, chemicals, and agriculture.

We present markets by end use segment (R&D, diagnostics/pharmaceuticals, energy, chemicals, and agriculture) and by product type (enabling products, biologic components, integrated systems, and enabled products). Key market segments are covered, including synthetic genes, chassis organisms, biofuels, specialty chemicals, and pharmaceuticals.

We analyze synthetic biology technologies, growth driving forces, market applications, industry structure and competitive dynamics, companies and industry alliances, future market potential, and product sales forecasts for the period 2011 through 2016. We project the future use of synthetic biology products in the main end user segments and by product type.

This report will be of particular interest to pharmaceuticals, chemicals, enzymes, energy, agricultural, biotechnology, and bionanobiotechnology companies, as well as suppliers of genomics tools, DNA synthesis, and DNA sequencing products. It will also be of high interest to professionals within governments and regulatory agencies to understand the scope and pace of synthetic biology technologies as they reach the market.

SCOPE AND FORMAT

The study’s scope includes core synthetic biology products (synthetic genes, other DNA parts, chassis organisms, synthetic cells), enabling technologies (DNA sequencing, oligonucleotides, specialty media, bioinformatics), and enabled technologies (biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture) that are already commercial or forecast to be commercialized within the next 5 years.

We analyze key synthetic biology technologies and products to determine present and future market status, and forecast growth from 2011 through 2016. We also discuss strategic alliances, industry structures, competitive dynamics, patent strategy, and market driving forces.

BCC examines the synthetic biology industry by market segment, including suppliers of synthetic genes, enzymes, pharmaceutical companies, biofuels, and specialty chemicals. The role of key strategic alliances from 2009 through 2011 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, and chassis organisms are analyzed, as well as metabolically-engineered factories for producing synthetic fuels and specialty chemicals. The main companies in these fields are highlighted.

METHODOLOGY

BCC surveys key users and producers in each of the end user market segments and technology fields that will be commercially important during the next 5 years. Discussions with industry thought leaders, as well as secondary market research was performed.

Based on our analysis, we project the future applications of synthetic biology technologies in the major end user market segments and by technology type, and forecast sales revenues for 2011 through 2016.

INFORMATIION SOURCES

BCC surveyed leading synthetic biology, biotechnology, pharmaceutical, chemical, and energy companies to obtain data for this study. Included were life science research tools, drug, biotechnology, DNA synthesis and sequencing, and microfluidics firms, as well as leading life science research institutions. We also obtained inputs from leading academic and industry thought leaders. Data from secondary sources included industry, trade, and government publications.

Table Of Contents

Table of Contents

CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 2
SCOPE AND FORMAT 3
METHODOLOGY 3
INFORMATION SOURCES 3
RELATED BCC REPORTS 4
ANALYST CREDENTIALS 4
BCC ON-LINE SERVICES 4
DISCLAIMER 4
DISCLAIMER (CONTINUED) 5
CHAPTER TWO: SUMMARY 6
SUMMARY TABLE GLOBAL VALUE OF SYNTHETIC BIOLOGY
MARKET, BY PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL VALUE OF SYNTHETIC BIOLOGY
MARKET, BY PRODUCT TYPE, 2010-2016 ($ MILLIONS) 7
SUMMARY (CONTINUED) 8
CHAPTER THREE: OVERVIEW 9
SYNTHETIC BIOLOGY TECHNOLOGIES COVERED IN THIS
REPORT 9
TABLE 1 SCOPE OF THIS REPORT 9
FIGURE 1 SYNTHETIC BIOLOGY VALUE-ADDED CHAIN 10
WHAT IS SYNTHETIC BIOLOGY? 10
DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY 11
FIGURE 2 FROM THE NATURAL TO THE ARTIFICIAL 12
FORCES DRIVING SYNTHETIC BIOLOGY MARKET GROWTH 13
TABLE 2 FORCES DRIVING THE GROWTH OF SYNTHETIC
BIOLOGY 13
GLOBAL MARKET POTENTIAL FOR SYNTHETIC BIOLOGY
PRODUCTS 14
TABLE 3 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY
END USER INDUSTRY, THROUGH 2016 ($ MILLIONS) 15
LIFE CYCLE STATUS OF PRODUCTS AND TECHNOLOGIES 15
TABLE 4 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY
LIFE CYCLE STAGE 16
THE SYNTHETIC BIOLOGY INDUSTRY 17
TABLE 5 SYNTHETIC BIOLOGY COMPETITORS BY MARKET
FOCUS 17
CHAPTER FOUR: SYNTHETIC BIOLOGY TECHNOLOGIES 18
INTRODUCTION 18
SYNTHETIC BIOLOGY DEFINED 18
TABLE 6 SYNTHETIC BIOLOGY DEFINITIONS 18
HISTORY OF SYNTHETIC BIOLOGY 19
TABLE 7 SYNTHETIC BIOLOGY HISTORY 19
TABLE 7 (CONTINUED) 20
History of Synthetic Biology (Continued) 21
PARADIGM SHIFT IN BIOLOGY 22
TABLE 8 PARADIGM SHIFT CAUSED BY SYNTHETIC BIOLOGY 22
TABLE 9 GENETIC ENGINEERING AND SYNTHETIC BIOLOGY
COMPARISON 23
Paradigm Shift In Biology (Continued) 24
FIGURE 3 SCALE OF SYNTHETIC BIOLOGY (BASE PAIRS) 25
SYNTHETIC BIOLOGY TECHNOLOGY OVERVIEW 26
TABLE 10 SYNTHETIC BIOLOGY APPLICATIONS BY TECHNOLOGY 26
ENABLING TECHNOLOGIES 27
TABLE 11 IMPORTANCE OF ENABLING TECHNOLOGIES 27
DNA SYNTHESIS AND SEQUENCING COST TRENDS 28
TABLE 12 COSTS TO SEQUENCE AND SYNTHESIZE A HUMAN
GENOME, 2001-2018 28
DNA SYNTHESIS TECHNOLOGIES 29
FIGURE 4 SCHEMATIC OF GENE SYNTHESIS TECHNOLOGIES 29
DNA Synthesis Technologies (Continued) 30
TABLE 13 COMPARISON OF GENE SYNTHESIS TECHNOLOGIES 31
PCR-based Approaches 31
Solid-phase Approaches 32
MICROFLUIDICS TECHNOLOGIES 33
TABLE 14 IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN
SYNTHETIC BIOLOGY 33
DNA Microarrays - Oligos Synthesis 33
TABLE 15 MICROARRAY TYPES 34
TABLE 16 DNA MICROARRAY PLATFORM FEATURES 34
TABLE 17 DNA MICROARRAY PLATFORM COMPARISON FOR
MAJOR MANUFACTURERS 35
TABLE 17 (CONTINUED) 36
DNA Microarrays - … (Continued) 37
FIGURE 5 MICROARRAYS IN GENE SYNTHESIS 38
DNA SEQUENCING TECHNOLOGIES 39
TABLE 18 WORKFLOW COMPARISON OF SELECTED NEXTGENERATION
DNA SEQUENCING PLATFORMS 39
TABLE 19 BIOCHIP CONTENT IN NEXT-GENERATION
SEQUENCING MACHINES 40
DNA Sequencing Technologies (Continued) 41
BIOINFORMATICS TECHNOLOGIES 42
TABLE 20 SYNTHETIC BIOLOGY BIOINFORMATICS
TECHNOLOGIES 43
BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS
TECHNOLOGIES 43
TABLE 21 NUCLEIC ACIDS, GENES, AND GENOMES 44
SYNTHETIC GENES 44
TABLE 22 SYNTHETIC GENES AS A MOLECULAR BIOLOGY TOOL 45
TABLE 23 SYNTHETIC GENES VERSUS PCR CLONING 46
Synthetic Genes (Continued) 47
BIOBRICK PARTS 48
TABLE 24 BIOBRICK PARTS 48
Biobrick Parts (Continued) 49
FIGURE 6 ROLE OF PROMOTERS AND REPORTERS IN
SYNTHETIC BIOLOGY SYSTEMS 50
MINIMAL GENOMES AND CHASSIS ORGANISMS 51
TABLE 25 ATTRIBUTES OF A MINIMAL GENOME 51
Case Study: Minimal E coli Genome 52
Role of Directed Evolution in Designing Biologic Parts 53
ENABLED TECHNOLOGIES 53
TABLE 26 ENABLED TECHNOLOGIES: EXISTING AND NEAR
TERM APPLICATIONS 54
PATHWAY ENGINEERING 54
FIGURE 7 HOW SYNTHETIC BIOLOGY CREATES ENABLED
PRODUCTS 55
TABLE 27 METABOLIC ENGINEERING FOR ARTEMISINIC ACID 56
SYNTHETIC MICROBIAL CONSORTIA 57
TABLE 28 APPLICATIONS FOR SYNTHETIC MICROBIAL
CONSORTIA 58
RESEARCH AND DEVELOPMENT APPLICATIONS 59
TABLE 29 RESEARCH and DEVELOPMENT APPLICATIONS FOR
SYNTHETIC BIOLOGY PRODUCTS 59
BIOFUELS TECHNOLOGIES 60
OVERVIEW 60
TABLE 30 ADVANCED BIOFUELS TYPES 61
FIRST AND SECOND GENERATION BIOFUELS
TECHNOLOGIES 62
TABLE 31 FIRST AND SECOND GENERATION BIOFUELS
COMPARED 62
CROP FEEDSTOCKS 63
TABLE 32 ENERGY BALANCE OF SELECTED FIRST GENERATION
BIOFUEL FEEDSTOCKS 64
CELLULOSIC FEEDSTOCKS 64
TABLE 33 APPROXIMATE COMPOSITION OF CELLULOSIC
BIOMASS (%) 64
TABLE 34 SYNTHETIC BIOLOGY STRATEGIES FOR CONVERTING
CELLULOSIC BIOMASS INTO ETHANOL 65
TABLE 35 BIOMASS ECONOMICS 66
ALGAE FEEDSTOCKS 66
TABLE 36 BIODIESEL YIELDS OF SELECTED CROPS 67
CARBON DIOXIDE FEEDSTOCKS 68
BIOFUEL END PRODUCTS 68
TABLE 37 EFFICIENCIES OF VARIOUS FUELS 69
Cellulosic Ethanol 69
FIGURE 8 CELLULOSIC ETHANOL PRODUCTION SCHEMATIC 70
Biodiesel 71
TABLE 38 IODINE NUMBER OF VARIOUS OILS 72
Other Biofuels 72
Role of Genetic Engineering and Synthetic Biology in
Biofuels 73
TABLE 39 CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS 73
Role of Genetic Engineering and … (Continued) 74
CHAPTER FIVE: SYNTHETIC BIOLOGY APPLICATIONS 75
INTRODUCTION 75
ENABLING TECHNOLOGIES APPLICATIONS 75
TABLE 40 SYNTHETIC BIOLOGY PRODUCTS IMPACTED BY
ENABLING TECHNOLOGIES 75
BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS
APPLICATIONS 76
TABLE 41 BIOLOGICAL COMPONENTS AND INTEGRATED
SYSTEMS NEAR-TERM APPLICATIONS 76
SYNTHETIC GENE APPLICATIONS 77
TABLE 42 SYNTHETIC GENES NEAR-TERM APPLICATIONS 77
Synthetic Gene Applications (Continued) 78
BIOBRICK PARTS APPLICATIONS 79
Biobrick Parts Applications (Continued) 80
INTEGRATED SYSTEMS APPLICATIONS 81
TABLE 43 E COLI AS A CHASSIS ORGANISM 81
Integrated Systems Applications (Continued) 82
Synthetic Cells and Tissues 83
Cellular Factories 83
ENABLED PRODUCT APPLICATIONS 83
PHARMACEUTICALS 84
TABLE 44 SYNTHETIC BIOLOGY-ENABLED DRUG CLASSES 84
TABLE 45 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS
FOR SYNTHETIC BIOLOGY PRODUCTS 85
TABLE 46 SYNTHETIC BIOLOGY-ENABLED PHARMACEUTICAL
APPLICATIONS 86
Pharmaceuticals (Continued) 87
DIAGNOSTICS 88
TABLE 47 SYNTHETIC BIOLOGY-ENABLED DIAGNOSTICS
APPLICATIONS 88
BIOFUELS 89
TABLE 48 SYNTHETIC BIOLOGY-ENABLED BIOFUELS
APPLICATIONS 89
TABLE 49 GROWTH STATUS OF SPECIALTY VERSUS DROP-IN
BIOFUELS, 2000-2020 90
CHEMICALS 90
TABLE 50 SYNTHETIC BIOLOGY-ENABLED CHEMICALS
APPLICATIONS 90
TABLE 50 (CONTINUED) 91
ENGINEERED PLANTS AND INSECTS 91
TABLE 51 SYNTHETIC BIOLOGY-ENABLED ENGINEERED PLANTS
AND INSECTS APPLICATIONS 92
PRODUCTION PROCESSES 92
TABLE 52 SYNTHETIC BIOLOGY-ENABLED PRODUCTION
PROCESSES APPLICATIONS 93
CHAPTER SIX: SYNTHETIC BIOLOGY INDUSTRY 94
INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN 94
FIGURE 9 INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH
SYNTHETIC BIOLOGY LEVERAGE POINTS 95
INDUSTRY STRUCTURAL FORCES 96
TABLE 53 SYNTHETIC BIOLOGY INDUSTRY STRUCTURAL FORCES 96
INDUSTRY STRUCTURAL FORCES (CONTINUED) 97
PRODUCTS AND TECHNOLOGY LIFE CYCLE 98
TABLE 54 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY
LIFE CYCLE STAGES 98
GENE SYNTHESIS INDUSTRY 99
GENE SYNTHESIS WORKFLOW 99
TABLE 55 GENE SYNTHESIS WORKFLOW 99
Gene Synthesis Workflow (Continued) 100
GENE SYNTHESIS COMPETITORS 101
TABLE 56 SYNTHETIC GENE COMPANY ESTIMATED 2010 MARKET
SHARES ($ MILLIONS/%) 102
Gene Synthesis Competitors (Continued) 103
TABLE 57 SYNTHETIC GENE KEY COMPETITOR STRATEGIES 104
GENE SYNTHESIS VALUE CHAIN 105
SYNTHETIC GENE MARKET SEGMENTS 106
Automated Standardized Segment 107
Value Added Segment 107
TABLE 58 GENE SYNTHESIS MARKET FACTORS OF
DIFFERENTIATION 108
BIOFUELS INDUSTRY 109
COMPETITIVE DIFFERENTIATION 109
FEEDSTOCKS 109
TABLE 59 BIOFUELS: FEEDSTOCKS, PRODUCTION AND
PRODUCTS 110
TABLE 60 BIOFUELS FEEDSTOCKS: RELATIVE SUPPLY VOLUME
AND COSTS 111
Sugars/Starches 111
Vegetable Oils 111
Biomasses 111
Algae 112
CO2 112
BIOFUEL COMPETITOR STRATEGIES 112
TABLE 61 SYNTHETIC BIOLOGY BIOFUELS COMPANY
STRATEGIES 113
TABLE 61 (CONTINUED) 114
Biofuel Competitor Strategies (Continued) 115
Biofuel Competitor Strategies (Continued) 116
Biofuel Competitor Strategies (Continued) 117
CHEMICALS INDUSTRY 118
TABLE 62 SYNTHETIC BIOLOGY-ENABLED CHEMICALS
APPLICATIONS 118
TABLE 63 VALUE-ADDED IN SELECTED END MARKETS 119
ENZYMES INDUSTRY 120
TABLE 64 ENZYME COMPANY KEY ALLIANCES 120
TABLE 64 (CONTINUED) 121
PHARMACEUTICALS INDUSTRY 122
TABLE 65 SYNTHETIC BIOLOGY-ENABLED DRUG STRATEGIES 122
TABLE 65 (CONTINUED) 123
ACQUISITIONS AND STRATEGIC ALLIANCES 124
TABLE 66 SYNTHETIC BIOLOGY INDUSTRY ACQUISITIONS, 2010-
2011 125
Acquisitions and Strategic Alliances (Continued) 126
Acquisitions and Strategic Alliances (Continued) 127
TABLE 67 STRATEGIC ALLIANCES, 2009-2011 128
TABLE 67 (CONTINUED) 129
TABLE 67 (CONTINUED) 130
TABLE 67 (CONTINUED) 131
Acquisitions and Strategic Alliances (Continued) 132
Acquisitions and Strategic Alliances (Continued) 133
Acquisitions and Strategic Alliances (Continued) 134
Acquisitions and Strategic Alliances (Continued) 135
Acquisitions and Strategic Alliances (Continued) 136
Acquisitions and Strategic Alliances (Continued) 137
Acquisitions and Strategic Alliances (Continued) 138
CHAPTER SEVEN: SYNTHETIC BIOLOGY MARKETS 139
INDUSTRY GROWTH DRIVING FORCES 139
TABLE 68 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES 139
INDUSTRY GROWTH DRIVING FORCES (CONTINUED) 140
MACROECONOMIC FORECASTING ASSUMPTIONS 141
FIGURE 10 MARKET FORECAST SCENARIO TABLE 142
SYNTHETIC BIOLOGY MARKETS BY END USER INDUSTRY 143
TABLE 69 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY
END USER INDUSTRY, THROUGH 2016 ($ MILLIONS) 143
RandD MARKET 144
TABLE 70 GLOBAL VALUE OF RandD MARKET, BY PRODUCT TYPE,
THROUGH 2016 ($ MILLIONS) 144
DIAGNOSTICS AND PHARMACEUTICALS MARKET 145
TABLE 71 GLOBAL VALUE OF DIAGNOSTICS/PHARMACEUTICALS
MARKET, BY PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 145
Diagnostics and Pharmaceuticals Market (Continued) 146
CHEMICALS MARKET 147
TABLE 72 GLOBAL VALUE OF CHEMICALS MARKET, BY PRODUCT
TYPE, THROUGH 2016 ($ MILLIONS) 148
ENERGY MARKET 148
TABLE 73 GLOBAL VALUE OF ENERGY MARKET, BY PRODUCT
TYPE, THROUGH 2016 ($ MILLIONS) 149
AGRICULTURE MARKET 149
TABLE 74 GLOBAL VALUE OF AGRICULTURE MARKET, BY
PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 150
SYNTHETIC BIOLOGY MARKETS BY PRODUCT TYPE 150
SUMMARY 150
TABLE 75 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY
PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 151
ENABLING PRODUCTS MARKETS 152
TABLE 76 GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLING
PRODUCTS, BY TYPE, THROUGH 2016 ($ MILLIONS) 152
TABLE 77 GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLING
PRODUCTS, BY INDUSTRY, THROUGH 2016 ($ MILLIONS) 153
BIOLOGIC COMPONENTS MARKET 154
TABLE 78 GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET,
BY TYPE, THROUGH 2016 ($ MILLIONS) 155
Synthetic Gene Standardized Market Segment 155
Synthetic Gene Value-added Market Segment 155
TABLE 79 GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET,
BY INDUSTRY, THROUGH 2016 ($ MILLIONS) 156
Synthetic Gene Value-… (Continued) 157
INTEGRATED SYSTEMS MARKET 158
TABLE 80 BIOLOGICAL COMPONENTS AND INTEGRATED
SYSTEMS NEAR-TERM APPLICATIONS 158
TABLE 81 GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET,
BY TYPE, THROUGH 2016 ($ MILLIONS) 158
Integrated Systems Market (Continued) 159
TABLE 82 GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET,
BY INDUSTRY, THROUGH 2016 ($ MILLIONS) 160
ENABLED PRODUCTS MARKET 160
SOURCES OF COMPETITIVE ADVANTAGE 160
TABLE 83 BIODIESEL FUEL PERFORMANCE COMPARISON 161
TABLE 84 ARTEMISININ DRUG PRODUCTION COMPARISON 162
TABLE 85 GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLED
PRODUCTS MARKET, BY INDUSTRY, THROUGH 2016 ($
MILLIONS) 162
DIAGNOSTICS AND PHARMACEUTICALS MARKET 163
TABLE 86 GLOBAL VALUE OF ENABLED DIAGNOSTIC AND
PHARMACEUTICALS MARKET, BY INDUSTRY, THROUGH 2016 ($
MILLIONS) 164
TABLE 87 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED
DIAGNOSTICS MARKET, BY INDICATION, THROUGH 2016 ($
MILLIONS) 164
TABLE 88 GLOBAL VALUE OF ENABLED PHARMACEUTICALS
MARKET, BY DRUG CLASS, THROUGH 2016 ($ MILLIONS) 165
Diagnostics and Pharmaceuticals Market (Continued) 166
CHEMICALS MARKET 167
TABLE 89 GLOBAL VALUE OF ENABLED CHEMICALS MARKET, BY
PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 168
BIOFUELS MARKET 169
TABLE 90 ADVANCED BIOFUEL GROWTH DRIVING FACTORS 170
TABLE 91 PUBLIC AND PRIVATE FUNDING FOR SELECTED
BIOFUELS COMPANIES 171
TABLE 92 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED
BIOFUELS MARKET, BY FUEL TYPE, THROUGH 2016 ($
MILLIONS) 172
AGRICULTURE MARKET 173
TABLE 93 GLOBAL VALUE OF AGRICULTURE MARKET, BY
APPLICATION, THROUGH 2016 ($ MILLIONS) 173
ALL PRODUCTS BY GEOGRAPHY 174
TABLE 94 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY
GEOGRAPHY, THROUGH 2016 ($ MILLIONS) 175
ENABLING PRODUCTS MARKET BY GEOGRAPHY 176
TABLE 95 GLOBAL VALUE OF ENABLING PRODUCTS MARKET, BY
GEOGRAPHY, THROUGH 2016 ($ MILLIONS) 176
CORE PRODUCTS BY GEOGRAPHY 176
TABLE 96 GLOBAL VALUE OF CORE PRODUCTS MARKET, BY
GEOGRAPHY, THROUGH 2016 ($ MILLIONS) 177
ENABLED PRODUCTS BY GEOGRAPHY 177
TABLE 97 GLOBAL VALUE OF ENABLED PRODUCTS MARKET, BY
GEOGRAPHY, THROUGH 2016($ MILLIONS) 178
Enabled Products by Geography (Continued) 179
CHAPTER EIGHT: PATENTS 180
INTRODUCTION 180
TABLE 98 SYNTHETIC BIOLOGY PATENT SCOPE 181
FOUNDATIONAL PATENTS 181
TABLE 99 SYNTHETIC BIOLOGY FOUNDATIONAL PATENTS 182
Enabled Products by Geography (Continued) 183
SYNTHETIC BIOLOGY INDUSTRY PATENT ANALYSIS 184
FIGURE 11 NUMBER OF PATENTS BY COMPANY 185
FIGURE 11 (CONTINUED) 186
FIGURE 12 PATENTS BY COMPANY AND SUBCLASS 187
FIGURE 12 (CONTINUED) 188
TABLE 100 PATENT DESCRIPTION BY COMPANY 189
TABLE 100 (CONTINUED) 190
PATENT STRATEGY OF SELECTED COMPANIES 191
METABOLIX 191
DUPONT 191
GENEART (LIFE TECHNOLOGIES) 192
FEBIT 192
BIOTICA 193
CHAPTER NINE: COMPANY PROFILES 194
AGRIVIDA 194
TABLE 101 AGRIVIDA TECHNICAL APPROACH 194
ALGENICS 195
ALGENOL BIOFUELS 196
ALLOPARTIS BIOTECHNOLOGIES, INC 196
ALLYLIX 197
AMBRX, INC 197
AMYRIS BIOTECHNOLOGIES, INC 198
TABLE 102 AMYRIS SPECIALTY CHEMICALS STRATEGY 199
TABLE 103 AMYRIS BIODIESEL ADVANTAGES 200
ATG BIOSYNTHETICS GMBH 201
BASF AG 202
BAYER AG 203
BIOAMBER INC 203
BIOBASIC INC 204
BIOCALDOL LTD 204
BIOCAT GMBH 204
BIONEER CORPORATION 205
BIONEXUS INC 206
BIOSEARCH TECHNOLOGIES, INC 206
BIO SandT, INC 207
BIOTICA TECHNOLOGY LTD 207
BIOTICA TECHNOLOGY LTD (CONTINUED) 208
TABLE 104 STRUCTURE-FUNCTION APPROACH FOR RAPAMYCIN 209
BLUE MARBLE ENERGY 210
BRISTOL MYERS SQUIBB 210
BRISTOL MYERS SQUIBB (CONTINUED) 211
BRITISH PETROLEUM 212
COBALT TECHNOLOGIES 213
CODEXIS, INC 214
DANISCO A/S 215
DNA20 216
DNA20 (CONTINUED) 217
DOW CHEMICAL COMPANY 218
DRATHS CORPORATION 218
DRATHS CORPORATION (CONTINUED) 219
EI DU PONT DE NEMOURS AND COMPANY 220
EI DU PONT DE NEMOURS …(CONTINUED) 221
DYADIC INTERNATIONAL 222
ENTELECHON GMBH 222
EPOCH LIFE SCIENCE, INC 223
EUROFINS MWG OPERON 224
EVOLVA SA 224
TABLE 105 EVOLVA’S GENETIC CHEMISTRY PLATFORM 225
TABLE 106 EVOLVA STRATEGIC ALLIANCES 226
TABLE 107 EVOLVA PRODUCT PIPELINE 226
EXXONMOBIL CORPORATION 227
FEBIT HOLDING GMBH 228
FLUXOME A/S 229
GENEMED SYNTHESIS INC 229
GENEWORKS PTY LTD 230
GENEORACLE, INC 230
GENOMATICA 230
GENSCRIPT USA INC 231
GEVO, INC 232
GINKGO BIOWORKS 233
GLYCOS BIOTECHNOLOGIES, INC 234
GOODYEAR TIRE and RUBBER 234
GREEN BIOLOGICS LTD 235
ILLUMINA, INC 235
ILLUMINA, INC (CONTINUED) 236
INGENZA LTD 237
INTEGRATED DNA TECHNOLOGIES, INC 238
INSTITUTE FOR ONEWORLD HEALTH 238
IOGEN CORPORATION 239
INTREXON CORPORATION 239
TABLE 108 INTREXON ULTRAVECTOR PARTS INVENTORY
EXAMPLES 240
JOULE UNLIMITED 241
KIVERDI, INC 242
LC SCIENCES 242
LIFE TECHNOLOGIES, INC 243
LIFE TECHNOLOGIES, INC (CONTINUED) 244
LS9, INC 245
LUMINEX 246
MASCOMA 247
MERCK and CO 248
METABOLIX INC 248
TABLE 109 MIREL’S COMPETITORS IN BIOPLASTICS 249
METRIGEN, INC 250
MODULAR GENETICS 250
MORPHOSYS AG 250
MYRIANT TECHNOLOGIES 251
NEW ENGLAND BIOLABS 252
NOVACTA BIOSYSTEMS LTD 253
NOVOZYMES A/S 253
OMEGA BIO-TEK, INC 254
OPX BIOTECHNOLOGIES, INC 255
ORIGENE TECHNOLOGIES 256
OXITEC LTD 256
PACIFIC BIOSCIENCES 257
PFIZER 258
PROTERRO INC 259
PROTOLIFE SRL 260
QTEROS, INC 260
RENNOVIA, INC 261
ROCHE LIFE SCIENCES 261
ROYAL DSM NV 262
SANGAMO BIOSCIENCES, INC 263
TABLE 110 SANGAMO STRATEGIC ALLIANCES 264
SANGAMO BIOSCIENCES, INC (CONTINUED) 265
SANOFI AVENTIS 266
SAPPHIRE ENERGY 267
SCARAB GENOMICS, LLC 267
SHANGHAI GENERAY BIOTECH CO, LTD 268
SHANGHAI SHINEGENE MOLECULAR BIO-TECHNOLOGIES,
INC 268
SOLAZYME, INC 269
TABLE 111 SOLAZYME STRATEGIC ALLIANCES 270
SUTRO BIOPHARMA, INC 271
SWITCHGEAR GENOMICS 271
SYNPROMICS LTD 272
SYNTHETIC GENOMICS INC 272
SYNTHETIC GENOMICS INC (CONTINUED) 273
TABLE 112 SYNTHETIC GENOMICS STRATEGIC ALLIANCES 274
THERMO FISHER SCIENTIFIC 275
VERDEZYNE, INC 275
VERENIUM CORPORATION 276
VERENIUM CORPORATION (CONTINUED) 277
VIRAL GENETICS INC 278
ZIOPHARM ONCOLOGY, INC 278
ZIOPHARM ONCOLOGY, INC (CONTINUED) 279

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Synthetic Biology : Global Markets

Synthetic Biology : Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Synthetic biology is an emerging biotechnology discipline with a wide range of applications. This BCC Research report determines the specific applications and forecast global market demand for synthetic ...

Synthetic Biology Market (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019

Synthetic Biology Market (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019

  • $ 4 795
  • Industry report
  • April 2014
  • by Transparency Market Research

Synthetic biology defined as the synthesis of artificial or natural components in order to form new artificial living system by re-molding existing biological elements. It aims to attain new preferred ...

Transfection Technology Market (Reagent-based method, Instrument-based method and Virus-based method) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Transfection Technology Market (Reagent-based method, Instrument-based method and Virus-based method) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

  • $ 4 795
  • Industry report
  • April 2014
  • by Transparency Market Research

Transfection is a technique used to introduce nucleic acids (either DNA or RNA) into cells. This technology helps the cells to regulate gene therapy, mutation of cancer cells and protein metabolism by ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.